Navigation Links
Genomic Health Announces Appointment of Ginger Graham to Board of Directors

REDWOOD CITY, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the appointment of Ginger L. Graham to its board of directors. Ms. Graham is the former President and CEO of Amylin Pharmaceuticals, Inc.; a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with diabetes and obesity. Prior to Amylin, Ms. Graham served as Group Chairman, Office of the President, for Guidant Corporation, a cardiovascular medical device manufacturer, and held a number of management positions at Eli Lilly and Company, a global pharmaceutical company.

"Ginger brings a wealth of industry leadership experience to Genomic Health's board of directors, with expertise in developing and commercializing successful products for pharmaceutical and medical device companies," said Randy Scott, Ph.D., chairman and CEO of Genomic Health. "Her appointment comes at an opportune time as we continue to expand our commercial efforts outside of the United States and invest in our product pipeline, as part of our mission to make individualized treatment standard practice for all cancer patients."

Ms. Graham received a Bachelor of Science in agricultural economics from the University of Arkansas. She also holds a Master of Business Administration from Harvard University.

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. Oncotype DX has been extensively evaluated in eleven clinical studies involving more than 4,000 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 75,000 tests, and both Medicare and private health plans covering approximately 90 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's mission to make individualized treatment standard practice for cancer patients, the ability of the company to continue to expand its commercial efforts outside of the United States and the ability of the company to continue to invest in its product pipeline. These risks and uncertainties include, but are not limited to: the results of additional clinical studies; the applicability of clinical study results to actual outcomes; the risk that we may not obtain or maintain sufficient levels of reimbursement for our test; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to develop new tests; our ability to obtain capital when needed; our history of operating losses and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended September 30, 2008. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
3. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
4. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
5. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
6. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
7. Genomic Health to Present at Stephens Fall Investment Conference
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
10. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11. /C O R R E C T I O N -- Rosetta Genomics Ltd/
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology:
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):